ES2525952A1 - Combinación farmacéutica antineurítica y composiciones - Google Patents

Combinación farmacéutica antineurítica y composiciones Download PDF

Info

Publication number
ES2525952A1
ES2525952A1 ES201490063A ES201490063A ES2525952A1 ES 2525952 A1 ES2525952 A1 ES 2525952A1 ES 201490063 A ES201490063 A ES 201490063A ES 201490063 A ES201490063 A ES 201490063A ES 2525952 A1 ES2525952 A1 ES 2525952A1
Authority
ES
Spain
Prior art keywords
compositions
antineuritic
pharmaceutical combination
combinations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201490063A
Other languages
English (en)
Other versions
ES2525952B1 (es
Inventor
Héctor SENOSIAIN ARROYO
Maria Angélica ARZOLA PANIAGUA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Senosiain SA de CV
Original Assignee
Laboratorios Senosiain SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48611941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2525952(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Senosiain SA de CV filed Critical Laboratorios Senosiain SA de CV
Publication of ES2525952A1 publication Critical patent/ES2525952A1/es
Application granted granted Critical
Publication of ES2525952B1 publication Critical patent/ES2525952B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Combinación farmacéutica antineurítica y composiciones. La presente invención se refiere a combinaciones farmacéuticas de dos antiepilépticos, así como combinaciones de un antiepiléptico, y vitaminas del complejo B, en donde los antiepilépticos se seleccionan de pregabalina y oxcarbazepina, y las vitaminas se seleccionan de vitamina B1 y vitamina B12. También se refiere a composiciones farmacéuticas que contienen dichas combinaciones y al uso de dichas composiciones para el tratamiento del dolor neuropático (DN).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21

Claims (1)

  1. imagen1
    imagen2
ES201490063A 2011-12-16 2012-12-14 Combinación farmacéutica antineurítica y composiciones Expired - Fee Related ES2525952B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MX/A/2011/014042 2011-12-16
MX2011014042A MX336979B (es) 2011-12-16 2011-12-16 Combinacion farmaceutica antineuritica y composiciones.
PCT/IB2012/057345 WO2013088410A1 (es) 2011-12-16 2012-12-14 Combinación farmacéutica antineurítica y composiciones

Publications (2)

Publication Number Publication Date
ES2525952A1 true ES2525952A1 (es) 2015-01-02
ES2525952B1 ES2525952B1 (es) 2015-10-05

Family

ID=48611941

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201490063A Expired - Fee Related ES2525952B1 (es) 2011-12-16 2012-12-14 Combinación farmacéutica antineurítica y composiciones

Country Status (14)

Country Link
US (1) US20140323428A1 (es)
BR (1) BR112014014774A2 (es)
CA (1) CA2859487C (es)
CL (1) CL2014001581A1 (es)
CO (1) CO6990712A2 (es)
CR (1) CR20140283A (es)
DO (1) DOP2014000134A (es)
ES (1) ES2525952B1 (es)
GT (1) GT201400115A (es)
MX (1) MX336979B (es)
NI (1) NI201400058A (es)
PE (1) PE20141688A1 (es)
PL (1) PL231163B1 (es)
WO (1) WO2013088410A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2826470B1 (en) * 2013-07-19 2017-09-06 Arven Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of pregabalin
MX2014008336A (es) 2014-07-07 2016-01-07 Pptm Internat S A R L Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico.
MX2023011799A (es) 2023-10-05 2025-05-02 Laboratorios Silanes S A De C V Tableta multiactivos en el tratamiento y control de dolor severo cronico y metodo de preparacion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070007276A (ko) * 2003-12-29 2007-01-15 제이슨 맥데빗 재발성 의학적 증상을 치료하기 위한 조성물 및 방법
US20100279984A1 (en) * 2007-10-09 2010-11-04 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
US8394759B2 (en) * 2008-11-21 2013-03-12 Cymbiotics, Inc. Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes

Also Published As

Publication number Publication date
US20140323428A1 (en) 2014-10-30
NI201400058A (es) 2014-12-22
WO2013088410A1 (es) 2013-06-20
DOP2014000134A (es) 2014-07-31
ES2525952B1 (es) 2015-10-05
CA2859487C (en) 2016-11-15
MX336979B (es) 2016-02-09
CO6990712A2 (es) 2014-07-10
CA2859487A1 (en) 2013-06-20
PL409542A1 (pl) 2015-07-20
BR112014014774A2 (pt) 2017-06-13
MX2011014042A (es) 2013-06-17
PE20141688A1 (es) 2014-12-03
GT201400115A (es) 2017-07-27
CL2014001581A1 (es) 2014-09-26
PL231163B1 (pl) 2019-01-31
CR20140283A (es) 2015-03-11

Similar Documents

Publication Publication Date Title
CO2017012786A2 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
CR20150326A (es) Inhibidores de autotaxina
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2016007067A (es) Microcapsulas lipidicas que comprenden de preferencia un retinoide y composicion que las contiene, su procedimiento de preparacion y su uso en dermatologia.
CO2018003466A2 (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
MX2017006785A (es) Metodos y composiciones para radioetiquetado con 18f de productos biologicos.
CU20140151A7 (es) Composición farmacéutica útil en la prevención de un evento cardiovascular mayor
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
DK3927338T3 (da) Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
UY34111A (es) Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
EA201591402A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
CL2015002837A1 (es) Compuestos de piridinilpirazoloquinolina.
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
CO2017002472A2 (es) Formulación de acetato de abiraterona
ECSP14017586A (es) Derivados de tetrahidro-quinazolinona
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CO6640301A2 (es) Compuestos ologo-benzamida y su uso
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
CL2012003006A1 (es) Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer.
ES2525952B1 (es) Combinación farmacéutica antineurítica y composiciones

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2525952

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20151005

FD2A Announcement of lapse in spain

Effective date: 20220426